Safety of switching between rituximab biosimilars in onco-hematology
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-85563-1
Abstract: Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different… read more here.
Keywords: hematology; safety; safety switching; rituximab biosimilars ... See more keywords
Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Therapy"
DOI: 10.1111/dth.12846
Abstract: Real-life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of psoriasis is lacking. We retrospectively analysed patient records from 69 patients with moderate to severe psoriasis treated at the… read more here.
Keywords: effectiveness safety; biosimilar infliximab; safety; infliximab etanercept ... See more keywords
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
Sign Up to like & getrecommendations! Published in 2019 at "Liver International"
DOI: 10.1111/liv.14017
Abstract: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and… read more here.
Keywords: tenofovir; hepatitis; dysfunction; kidney dysfunction ... See more keywords